SALT LAKE CITY, May 23, 2024 (GLOBE NEWSWIRE) Myriad Genetics, Inc., (NASDAQ: MYGN), a leader in genetic testing and precision medicine, and its collaborators will share data from seven
Molecular Residual Disease study and multiple RiskScore studies among seven new datasets to be shared by Myriad and Collaborators SALT LAKE CITY, May 23, 2024 Myriad Genetics, Inc., , a leader.
Myriad Genetics Showcases New Research and Product globenewswire.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from globenewswire.com Daily Mail and Mail on Sunday newspapers.
LONDON, May 16 /PRNewswire/ Eisai Europe Ltd announced today that results from 9 clinical data abstracts about compounds in the company s oncology pipeline, product portfolio and preclinical oncology research have been accepted for presentation at the 44th Annual Meeting of the American Society of Clinical Oncology (ASCO), taking place in Chicag
Sutro: Luveltamab Data At ESMO Signifies Continued ADC Advancement seekingalpha.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from seekingalpha.com Daily Mail and Mail on Sunday newspapers.